Welcome to LookChem.com Sign In|Join Free
  • or
Hebei yanxi chemical co.,LTD.Oxaliplatin Pharma API Paclitaxel Treatment of colorectal cancer CAS NO.61825-94-3//file1.lookchem.com/cas/reactions/2021/08/23/15700099.png
    x
  • Ms.faithe
  • Mr.peter
  • Mr.korol
  • Ms.nina
  • Ms.noa
qq

Communicate with Supplier:

Ms. xing
Ms. xing: What can I do for you?

Oxaliplatin Pharma API Paclitaxel Treatment of colorectal cancer CAS NO.61825-94-3 CAS NO.61825-94-3

MSDS/COA Download

FOB Price:
USD 1.00-3.00 /Kilogram Get Latest Price
Min.Order Quantity:
1 Kilogram
Purity:
99%
Port:
Qingdao port
Payment Terms:
T/T,Other

Add to Inquiry Cart

Product Details

Keywords

  • Oxaliplatin
  • Oxaliplatin supplier
  • 61825-94-3

Quick Details

  • ProName: Oxaliplatin Pharma API Paclitaxel Trea...
  • CasNo: 61825-94-3
  • Molecular Formula: C8H14N2O4Pt
  • Appearance: crystal, powder
  • Application: Pharmaceutical intermediates
  • DeliveryTime: 1-2 days
  • PackAge: as your request
  • Port: Qingdao port
  • ProductionCapacity: 10 Kilogram/Day
  • Purity: 99%
  • Storage: stay in dry, cool and well-sealed
  • Transportation: EMS,HK EMS,FEDEX,DHL,TNT
  • LimitNum: 1 Kilogram
  • Moisture Content: 0.01%
  • Impurity: 0.001%
  • Loss On Drying: 0.2%
  • Melting Point: 177℃ ~ 181℃
  • Specific Rotation: +27°
  • Assay: 99.2%

Superiority

reason for choosing us:

1): superior quality and competitive price:

our company is a renowned pharmaceutical manufacturer with more than 15 years experiences in china and all powders are supplying from our factory directly.

2): fast ,safe and well disguised delievery:

well-trained and disciplined packing team and sufficient stock ensure the parcel can be delieveried to your hand fastly and safely by dhl, tnt, fedex, hkems, ups, etc.

3): experienced in exporting:

we have clients throughout the world. products have been exported to germany, norway, poland, finland, spain, uk, france, russia, usa, brazil, mexico, australia, japan, korea, thailand, indonesia, uruguay and many other countries. custome pass rate ≥99%

4): flexible payment terms:

t/t,,money gram,bitcoin. there will always be a term that is convient to you.

5): warmhearted customer service and after-sale service:

the parcel's photos and tracking numbers will be sent to you once it is prepared. any of your questions would be solved for the first as soon as possible.

Details

  • quick details

    • proname: oxaliplatin pharma api paclitaxel tre...
    • casno: 61825-94-3
    • molecular formula: c8h14n2o4pt
    • appearance: white powder
    • application: pharmaceutical raw intermediates
    • deliverytime: within 10 days after receiving the pay...
    • package: a variety of packaging methods suitabl...
    • port: wuhan / shanghai / guangzhou ...
    • productioncapacity: 1000 metric ton/month
    • purity: 99%
    • storage: dry, dark and ventilated place
    • transportation: ems, hkems, dhl, tnt, ups, fedex.... ...
    • limitnum: 10 gram

    superiority

    1. hubei jusheng technology co., ltd., is a global chemical industry manufacturers and suppliers of pharmaceuticals and intermediates in china.
    2. the yearly production capacity is 50000mt, 80% for export.we have a professinal export team. both by air and by sea,we ensure that we meet the customer expectations with promptness.
    3. our company facing global high-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and rare chemicals trade. corey have well-equipped machine, strong technical force and considerate marketing team service.
    4. we also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.

    details

    oxaliplatin basic information
    adverse reactions and side effects production method
    product name: oxaliplatin
    synonyms: [sp-4-2-(1r-trans)]-(1,2-cyclohexanediamine-n,n')[ethanedioata(2-)-o,o']platinum;oxaliplatin;trans-l-diaminocyclohexane oxalatoplatinum;(1,2-cyclohexanediamine-n,n’)(ethanedioato(2-)-o,o’)-platinu(sp-4-2-(1r-tr;1-ohp;oxalato(1r,2r-cyclohexanediammine)platinum(ii);oxalatoplatin;oxalatoplatinum
    cas: 61825-94-3
    mf: c8h14n2o4pt
    mw: 397.29
    einecs: 274-613-9
    product categories: pharmaceutical material and intermeidates;active pharmaceutical ingredients;antineoplastic;intermediates & fine chemicals;pharmaceuticals;apis;amines;heterocycles;chemical reaction,pharm,electronic,materials;praxilene;inhibitors

    oxaliplatin chemical properties
    storage temp. store at +4°c
    form solid
    stability: stable. store cool. incompatible with oxidizing agents.
    safety information
    hazard codes xn,xi
    risk statements 36/37/38-40-42/43
    safety statements 26-36
    ridadr 2811
    wgk germany 3
    rtecs tp2275850
    hazardclass 6.1(a)
    packinggroup ii
    msds information
    provider language
    sigmaaldrich english
    oxaliplatin usage and synthesis
    treatment of colorectal cance oxaliplatin belongs to platinum derivatives for the treatment of patients with colorectal cancer metastasis after the failure of the clinical treatment through fluorouracil , it can be used alone or in combination with the use of fluorouracil, it is the third generation of new class of anti-tumor platinum compounds for colorectal cancer after cisplatin and carboplatin , and so far it has been the only envelope platinum drug which has a significant activity. the principle is by producing alkylation conjugate to act on dna, to form crosslinks within the chain and between the chain which inhibit dna synthesis and replication.at the same time, it can inhibit the hyperplasia of ovarian cancer and melanoma cell lines.
    august 2002, the us food and drug administration (fda) approved the sanofi saint raborg company's anticancer drug oxaliplatin (, eloxatin) for the second-line treatment of metastatic colon cancer.
    january 2004, the us food and drug administration (fda) formally approved the injection of oxaliplatin (eloxatin) and 5-fluorouracil (5fu) and leucovorin (lv) joint (folfox program) for the first-line treatment of advanced colorectal cancer.
    the domestic market is currently dominated by sanofi - aventis (eloxatin); jiangsu hengrui medicine co., ltd. (oxaliplatin); jiangsu nanjing pharmaceutical (austrian platinum) three manufacturers monopoly, which occupy more than 85% of the domestic market share .
    adverse reactions and side effect 1, the hematopoietic system: oxaliplatin has some hematologic toxicity. when administered alone,it can cause the following adverse reactions: anemia, leukopenia, neutropenia, thrombocytopenia, sometimes up to grade 3 or 4. when in combination with 5-fluorouracil , neutropenia and thrombocytopenia diseases’ hematological toxicity increases .
    2, the digestive system:when administered alone, it can cause nausea, vomiting, diarrhea. these symptoms sometimes are very serious. when in combination with 5-fluorouracil, these side effects are increased significantly. it is recommended to give preventive and / or therapeutic anti-emetic medication .
    3,the nervous system: peripheral neuritis, characterized by peripheral sensory neuropathy. sometimes there are accompanied around the mouth, upper respiratory tract and upper digestive tract spasms and sensory disorders.
    the above information is edited by the chemicalbook of tian ye.
    chemical propertie triangular flaky colorless crystals. the water solubility is 7.9mg / ml.
    for the treatment of colorectal cancer.
    production metho 5g of trans-cyclohexanediamine and 18g k2 (ptcl4) aqueous solution react at room temperature for 12h, to give 12g intermediate product (i). 6: 8g of silver nitrate is added to 3g compound (i) aqueous solution , the mixture is stirred for 2 ~ 3h under the dark, then add 4.8g oxalic acid dipotassium salt, react for 8h at room temperature , oxaliplatin is obtained .
    chemical properties white crystalline solid
    usage third generation platinum complex. an antitumor agent with activity against colorectal cancer. cytotoxicity follows the formation of adducts with dna. antineoplastic.
    usage vasodilator
    usage a antitumor agent with activity against colorectal cancer. cytotoxicity follows the formation of adducts with dna
    biological activity antitumor agent that forms platinum-dna adducts. causes intra- and interstrand dna crosslinks blocking dna replication and transcription. displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin (cis-diaminodichloroplatinum ) and shows antitumor activity in cell lines with acquired cisplatin resistance.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)